Home
RAPT
RAPT News

Latest RAPT Therapeutics Inc. (RAPT) News on September 9, 2025

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

GlobeNewswire

13 days ago

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

GlobeNewswire

3 months ago

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know

Zacks

3 months ago

Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know

Rapt Therapeutics announces effective date for 1-for-8 reverse stock split

TipRanks

3 months ago

Rapt Therapeutics announces effective date for 1-for-8 reverse stock split

MT Newswires

3 months ago

RAPT Therapeutics Shares to Start Trading on a Split-Adjusted Basis Tuesday

RAPT Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

3 months ago

RAPT Therapeutics to Participate in Upcoming Investor Conferences

MT Newswires

4 months ago

UBS Adjusts Price Target on RAPT Therapeutics to $1 From $2, Maintains Neutral Rating

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

Zacks

4 months ago

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know

RAPT Therapeutics Reports First Quarter 2025 Financial Results

GlobeNewswire

4 months ago

RAPT Therapeutics Reports First Quarter 2025 Financial Results

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

GlobeNewswire

5 months ago

RAPT Therapeutics Deepens Expertise in Allergic Diseases with Appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development

RAPT Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire

6 months ago

RAPT Therapeutics to Participate in Upcoming Investor Conferences

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

6 months ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Hanmi Pharmaceuticals reports data from trial of Tivumecirnon for gastric cancer

Clinical Trials Arena

7 months ago

Hanmi Pharmaceuticals reports data from trial of Tivumecirnon for gastric cancer

All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy

Zacks

7 months ago

All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

8 months ago

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

GlobeNewswire

8 months ago

RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors

Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

TipRanks

8 months ago

Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

MT Newswires

8 months ago

RAPT Therapeutics Shares Surge After HC Wainwright Upgrade

Progressive, EverQuote upgraded: Wall Street's top analyst calls

The Fly

8 months ago

Progressive, EverQuote upgraded: Wall Street's top analyst calls

MT Newswires

8 months ago

HC Wainwright Upgrades RAPT Therapeutics to Buy From Neutral, Price Target is $10

RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement

Pharmaceutical Technology

9 months ago

RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement

MT Newswires

9 months ago

Wells Fargo Raises RAPT Therapeutics' Price Target to $6 From $4, Overweight Rating Maintained

Why RAPT Therapeutics Stock Gained Over 100% On Monday?

Benzinga

9 months ago

Why RAPT Therapeutics Stock Gained Over 100% On Monday?

MT Newswires

9 months ago

RAPT Therapeutics, Shanghai Jemincare Sign Exclusive License Deal for Potential Food Allergy Treatment; Shares Up Pre-Bell

RAPT Therapeutics Announces $150 Million Private Placement

GlobeNewswire

9 months ago

RAPT Therapeutics Announces $150 Million Private Placement

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

GlobeNewswire

9 months ago

RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement for Novel Long-Acting anti-IgE Antibody

MT Newswires

10 months ago

Stifel Nicolaus Downgrades RAPT Therapeutics to Hold From Buy, Cuts Price Target to $2 From $7

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

GlobeNewswire

10 months ago

RAPT Therapeutics Reports Third Quarter 2024 Financial Results

MT Newswires

10 months ago

Top Midday Decliners

MT Newswires

10 months ago

JPMorgan Downgrades RAPT Therapeutics to Underweight From Neutral; Shares Plunge

RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull

Clinical Trials Arena

10 months ago

RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull

MT Newswires

10 months ago

RAPT Therapeutics Ends Zelnecirnon Program After FDA Hold on Trials

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

GlobeNewswire

10 months ago

Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

Simply Wall St.

10 months ago

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now

Insider Monkey

a year ago

RAPT Therapeutics, Inc. (RAPT): Worst 52-Week Low Stock to Buy Now

RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability

Insider Monkey

a year ago

RAPT Therapeutics, Inc. (RAPT) Stock Falls Following FDA Setback; Short Sellers Cite Unprofitability

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

RAPT Therapeutics Reports Second Quarter 2024 Financial Results

MT Newswires

a year ago

RAPT Therapeutics to Cut 40% Workforce -- Shares Down

Should You Sell Your Stake in RAPT Therapeutics (RAPT)?

Insider Monkey

a year ago

Should You Sell Your Stake in RAPT Therapeutics (RAPT)?

Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround

Zacks

a year ago

Down -15.94% in 4 Weeks, Here's Why Rapt Therapeutics (RAPT) Looks Ripe for a Turnaround

Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a year ago

Rapt Therapeutics (RAPT) Loses -47.08% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MT Newswires

a year ago

Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform

Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks

Zacks

a year ago

Here's Why Rapt Therapeutics (RAPT) is Poised for a Turnaround After Losing -52.88% in 4 Weeks

Here's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Watching RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Situation

GuruFocus.com

a year ago

RAPT Therapeutics Inc. Reports Q1 2024 Earnings: A Detailed Financial Overview

MT Newswires

a year ago

Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy

MT Newswires

a year ago

Barclays Downgrades RAPT Therapeutics to Equalweight, Price Target at $4

What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?

Benzinga

a year ago

What's Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?

MT Newswires

a year ago

Sector Update: Health Care Stocks Higher Late Afternoon

MT Newswires

a year ago

RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials

RAPT Therapeutics Reports First Quarter 2024 Financial Results

GlobeNewswire

a year ago

RAPT Therapeutics Reports First Quarter 2024 Financial Results

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

GlobeNewswire

a year ago

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

What Makes RAPT Therapeutics (RAPT) an Investment Choice?

Insider Monkey

a year ago

What Makes RAPT Therapeutics (RAPT) an Investment Choice?

Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?

Zacks

2 years ago

Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

2 years ago

RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire

2 years ago

RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting

Insider Buyers Lose Additional US$63k As RAPT Therapeutics Dips To US$236m

Simply Wall St.

2 years ago

Insider Buyers Lose Additional US$63k As RAPT Therapeutics Dips To US$236m

Rapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Tests

Investor's Business Daily

2 years ago

Rapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Tests

RAPT Therapeutics Stock Is Down 64%. FDA Halts 2 Studies After Liver Failure.

Barrons.com

2 years ago

RAPT Therapeutics Stock Is Down 64%. FDA Halts 2 Studies After Liver Failure.

Reuters

2 years ago

UPDATE 1-FDA puts on hold two Rapt Therapeutics mid-stage drug trials

Reuters

2 years ago

RAPT Therapeutics says FDA puts two mid-stage trials of company's drug on hold

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

GlobeNewswire

2 years ago

RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon

FDA puts hold on Rapt trials of drug for eczema, asthma

BioPharma Dive

2 years ago

FDA puts hold on Rapt trials of drug for eczema, asthma

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

GlobeNewswire

2 years ago

RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

2 years ago

RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Is It Too Late to Buy Tilray Brands Stock?

Motley Fool

2 years ago

Is It Too Late to Buy Tilray Brands Stock?

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 01/30/2024

Argus Research

2 years ago

Daily – Vickers Top Insider Picks for 01/29/2024

Johnson & Johnson Faces a 1.03% Portfolio Impact in Eaton Vance Worldwide Health Sciences ...

GuruFocus.com

2 years ago

Johnson & Johnson Faces a 1.03% Portfolio Impact in Eaton Vance Worldwide Health Sciences ...

Bel Fuse (BELFB) Declines More Than Market: Some Information for Investors

Zacks

2 years ago

Bel Fuse (BELFB) Declines More Than Market: Some Information for Investors

Can This $100 Billion Cybersecurity Stock Help You Retire a Millionaire?

Motley Fool

2 years ago

Can This $100 Billion Cybersecurity Stock Help You Retire a Millionaire?

GuruFocus.com

2 years ago

Hilltop Holdings Inc (HTH) Reports Mixed Financial Results for Q4 and Full Year 2023

Associated Press Finance

2 years ago

Hilltop Holdings: Q4 Earnings Snapshot

Business Wire

2 years ago

Hilltop Holdings Inc. Announces Financial Results for Fourth Quarter and Full Year 2023

Should Value Investors Buy Assurant (AIZ) Stock?

Zacks

2 years ago

Should Value Investors Buy Assurant (AIZ) Stock?

Kaplan Survey: Law Schools Concerned about Class Diversity, Amid Affirmative Action Ban Fallout

Business Wire

2 years ago

Kaplan Survey: Law Schools Concerned about Class Diversity, Amid Affirmative Action Ban Fallout

Eaton Vance Tax-mangd Glo Buy-write Oppo's Dividend Analysis

GuruFocus.com

2 years ago

Eaton Vance Tax-mangd Glo Buy-write Oppo's Dividend Analysis

Q3 Household Products Earnings Review: First Prize Goes to Clorox (NYSE:CLX)

StockStory

2 years ago

Q3 Household Products Earnings Review: First Prize Goes to Clorox (NYSE:CLX)

Business Wire

2 years ago

The New York Times Company to Announce Fourth-Quarter and Full-Year 2023 Financial Results on February 7, 2024

Bel Announces a New President of the Power and Protection Segment

GlobeNewswire

2 years ago

Bel Announces a New President of the Power and Protection Segment

Are Consumer Staples Stocks Lagging Coca-Cola Europacific Partners (CCEP) This Year?

Zacks

2 years ago

Are Consumer Staples Stocks Lagging Coca-Cola Europacific Partners (CCEP) This Year?

Canada Goose Stock (NYSE:GOOS): Benefit from Luxury Industry Panic

TipRanks

2 years ago

Canada Goose Stock (NYSE:GOOS): Benefit from Luxury Industry Panic

Strength Seen in Integer (ITGR): Can Its 3.8% Jump Turn into More Strength?

Zacks

2 years ago

Strength Seen in Integer (ITGR): Can Its 3.8% Jump Turn into More Strength?

Zacks.com featured highlights include Aspen Aerogels, AxoGen and Credo Technology Group

Zacks

2 years ago

Zacks.com featured highlights include Aspen Aerogels, AxoGen and Credo Technology Group

Caleres Reiterates Full Year 2023 Outlook

Business Wire

2 years ago

Caleres Reiterates Full Year 2023 Outlook

MercadoLibre (NASDAQ:MELI) Q3 Earnings: Leading The Online Marketplace Pack

StockStory

2 years ago

MercadoLibre (NASDAQ:MELI) Q3 Earnings: Leading The Online Marketplace Pack

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

2 years ago

RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

3 Charts For Investors to Watch Friday: Alphabet, Tesla, Altice USA

Investopedia

2 years ago

3 Charts For Investors to Watch Friday: Alphabet, Tesla, Altice USA

Here’s Why ZipRecruiter (ZIP) Declined in Q3

Insider Monkey

2 years ago

Here’s Why ZipRecruiter (ZIP) Declined in Q3

TELUS (TSE:T) shareholders have endured a 7.7% loss from investing in the stock a year ago

Simply Wall St.

2 years ago

TELUS (TSE:T) shareholders have endured a 7.7% loss from investing in the stock a year ago

OFG Bancorp (NYSE:OFG) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Simply Wall St.

2 years ago

OFG Bancorp (NYSE:OFG) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

Gogo Business Aviation's 5G Program Achieves Key Milestones

PR Newswire

2 years ago

Gogo Business Aviation's 5G Program Achieves Key Milestones

RLJ Lodging Trust Announces Dividends for Fourth Quarter of 2023

Business Wire

2 years ago

RLJ Lodging Trust Announces Dividends for Fourth Quarter of 2023

Ready Capital Corporation Declares Fourth Quarter 2023 Dividends

GlobeNewswire

2 years ago

Ready Capital Corporation Declares Fourth Quarter 2023 Dividends

Connection Achieves Microsoft Azure Expert MSP Renewal

Business Wire

2 years ago

Connection Achieves Microsoft Azure Expert MSP Renewal

Centerra Gold Inc.'s (TSE:CG) institutional investors lost 7.2% last week but have benefitted from longer-term gains

Simply Wall St.

2 years ago

Centerra Gold Inc.'s (TSE:CG) institutional investors lost 7.2% last week but have benefitted from longer-term gains

Lucid CFO resigns: Impact on stock, company outlook

Yahoo Finance Video

2 years ago

Lucid CFO resigns: Impact on stock, company outlook

Those who invested in AGCO (NYSE:AGCO) five years ago are up 145%

Simply Wall St.

2 years ago

Those who invested in AGCO (NYSE:AGCO) five years ago are up 145%

Oxford Industries, Inc. (NYSE:OXM) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Oxford Industries, Inc. (NYSE:OXM) Q3 2023 Earnings Call Transcript

Adams Natural Resources Fund Announces $19.96 Issue Price of Shares for Year-End Distribution Payable December 15, 2023

GlobeNewswire

2 years ago

Adams Natural Resources Fund Announces $19.96 Issue Price of Shares for Year-End Distribution Payable December 15, 2023

Share on Social Networks: